How Nanotechniques Could Vitalize the O-GlcNAcylation-Targeting Approach for Cancer Therapy

References

• Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259(5):3308–3317. doi:10.1016/S0021-9258(17)43295-9
   PubMed Web of Science ®Google Scholar
• Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18(7):452–465. doi:10.1038/nrm.2017.22
   PubMed Web of Science ®Google Scholar
• Matsuura A, Ito M, Sakaidani Y, et al. O-Linked N-Acetylglucosamine is present on the extracellular domain of Notch receptors. J Biol Chem. 2008;283(51):35486–35495. doi:10.1074/jbc.M806202200
   PubMed Web of Science ®Google Scholar
• Ogawa M, Senoo Y, Ikeda K, Takeuchi H, Okajima T. Structural divergence in O-GlcNAc Glycans displayed on epidermal growth factor-like repeats of mammalian Notch1. Molecules. 2018;23(7):1745. doi:10.3390/molecules23071745
   PubMed Web of Science ®Google Scholar
• Stateva SR, Villalobo A. O-GlcNAcylation of the human epidermal growth factor receptor. Org Biomol Chem. 2015;13(30):8196–8204. doi:10.1039/C5OB00443H
   PubMed Web of Science ®Google Scholar
• Wang L, Chen S, Zhang Z, et al. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer. BMC Cancer. 2018;18(1):1141. doi:10.1186/s12885-018-5033-y
   PubMed Web of Science ®Google Scholar
• Jang TJ. Differential membranous E-cadherin expression, cell proliferation and O-GlcNAcylation between primary and metastatic nodal lesion in colorectal cancer. Pathol Res Pract. 2016;212(2):113–119. doi:10.1016/j.prp.2015.12.003
   PubMed Web of Science ®Google Scholar
• Qian K, Wang S, Fu M, et al. Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer. J Biol Chem. 2018;293(36):13989–14000. doi:10.1074/jbc.RA118.004709
   PubMed Web of Science ®Google Scholar
• Chiaradonna F, Ricciardiello F, Palorini R. The nutrient-sensing hexosamine biosynthetic pathway as the Hub of cancer metabolic rewiring. Cells. 2018;7(6):53. doi:10.3390/cells7060053
   PubMed Web of Science ®Google Scholar
• Decourcelle A, Very N, Djouina M, et al. O-GlcNAcylation links nutrition to the epigenetic downregulation of UNC5A during colon carcinogenesis. Cancers. 2020;12(11):3168. doi:10.3390/cancers12113168
   PubMed Web of Science ®Google Scholar
• Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019;17(1):52. doi:10.1186/s12915-019-0671-3
   PubMed Web of Science ®Google Scholar
• Ferrer CM, Sodi VL, Reginato MJ. O-GlcNAcylation in cancer biology: linking metabolism and signaling. J Mol Biol. 2016;428(16):3282–3294. doi:10.1016/j.jmb.2016.05.028
   PubMed Web of Science ®Google Scholar
• Itkonen HM, Urbanucci A, Martin SE, et al. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. Theranostics. 2019;9(8):2183–2197. doi:10.7150/thno.30834
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hart GW. Targeting O-GlcNAcylation to develop novel therapeutics. Mol Aspects Med. 2021;79:100885. doi:10.1016/j.mam.2020.100885
   PubMed Web of Science ®Google Scholar
• Ju Kim E. O-GlcNAc transferase: structural characteristics, catalytic mechanism and small-molecule inhibitors. ChemBioChem. 2020;21(21):3026–3035. doi:10.1002/cbic.202000194
   PubMed Web of Science ®Google Scholar
• Franco Y, Vaidya T, Ait-Oudhia S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer Targets Ther. 2018;10:131–141.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra139. doi:10.1126/scitranslmed.3003651
   Web of Science ®Google Scholar
• Bloise N, Okkeh M, Restivo E, Della Pina C, Visai L. Targeting the “sweet side” of tumor with Glycan-binding molecules conjugated-nanoparticles: implications in cancer therapy and diagnosis. Nanomaterials. 2021;11(2):289. doi:10.3390/nano11020289
   Web of Science ®Google Scholar
• Jin L, Yuan F, Dai G, et al. Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett. 2020;25:17. doi:10.1186/s11658-020-00208-x
   PubMed Web of Science ®Google Scholar
• Asthana A, Ramakrishnan P, Vicioso Y, Zhang K, Parameswaran R. Hexosamine biosynthetic pathway inhibition leads to AML cell differentiation and cell death. Mol Cancer Ther. 2018;17(10):2226–2237. doi:10.1158/1535-7163.MCT-18-0426
   PubMed Web of Science ®Google Scholar
• Lemberg KM, Vornov JJ, Rais R, Slusher BS. We’re not “DON” yet: optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17(9):1824–1832. doi:10.1158/1535-7163.MCT-17-1148
   PubMed Web of Science ®Google Scholar
• Ricciardiello F, Votta G, Palorini R, et al. Inhibition of the hexosamine biosynthetic pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis. Cell Death Dis. 2018;9(3):377. doi:10.1038/s41419-018-0405-4
   PubMed Web of Science ®Google Scholar
• Borodkin VS, Schimpl M, Gundogdu M, et al. Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase inhibitors. Biochem J. 2014;457(3):497–502. doi:10.1042/BJ20131272
   PubMed Web of Science ®Google Scholar
• Jaskiewicz NM, Townson DH. Hyper-O-GlcNAcylation promotes epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget. 2019;10(30):2899–2910. doi:10.18632/oncotarget.26884
   PubMedGoogle Scholar
• Chariou PL, Ortega-Rivera OA, Steinmetz NF. Nanocarriers for the delivery of medical, veterinary, and agricultural active ingredients. ACS Nano. 2020;14(3):2678–2701. doi:10.1021/acsnano.0c00173
   PubMed Web of Science ®Google Scholar
• Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 2020;25(23):5672. doi:10.3390/molecules25235672
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–1598. doi:10.1016/S0959-8049(01)00171-X
   PubMed Web of Science ®Google Scholar
• An H-W, Mamuti M, Wang X, et al. Rationally designed modular drug delivery platform based on intracellular peptide self-assembly. Exploration. 2021;1(2):20210153. doi:10.1002/EXP.20210153
   Google Scholar
• Mei H, Cai S, Huang D, Gao H, Cao J, He B. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification. Bioact Mater. 2021;8:220–240. doi:10.1016/j.bioactmat.2021.06.035
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu S, Gu Z, Chen C, Zhao Y. Toxicity of manufactured nanomaterials. Particuology. 2022;69:31–48. doi:10.1016/j.partic.2021.11.007
   Web of Science ®Google Scholar
• Wang X, Cui X, Zhao Y, Chen C. Nano-bio interactions: the implication of size-dependent biological effects of nanomaterials. Sci China Life Sci. 2020;63(8):1168–1182. doi:10.1007/s11427-020-1725-0
   PubMed Web of Science ®Google Scholar
• Calvaresi EC, Hergenrother PJ. Glucose conjugation for the specific targeting and treatment of cancer. Chem Sci. 2013;4(6):2319–2333. doi:10.1039/c3sc22205e
   PubMed Web of Science ®Google Scholar
• Xu B, Zeng M, Zeng J, Feng J, Yu L. Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). Medicine. 2018;97(46):e13169–e13169. doi:10.1097/MD.0000000000013169
   PubMed Web of Science ®Google Scholar
• Tashima Y, Stanley P. Antibodies that detect O-linked β-D-N-acetylglucosamine on the extracellular domain of cell surface glycoproteins. J Biol Chem. 2014;289(16):11132–11142. doi:10.1074/jbc.M113.492512
   PubMed Web of Science ®Google Scholar
• Barua R, Mizuno K, Tashima Y, et al. Bioinformatics and functional analyses implicate potential roles for EOGT and L-fringe in pancreatic cancers. Molecules. 2021;26(4):882. doi:10.3390/molecules26040882
   PubMed Web of Science ®Google Scholar
• Wang L, Chen S, Zhang J, et al. Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma. Cancer Manag Res. 2019;11:2215–2223. doi:10.2147/CMAR.S190642
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yi W. Chemistry-assisted proteomic profiling of O-GlcNAcylation. Front Chem. 2021;9:702260. doi:10.3389/fchem.2021.702260
   PubMed Web of Science ®Google Scholar
• Lochner N, Pittner F, Wirth M, Gabor F. Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm Res. 2003;20(5):833–839. doi:10.1023/A:1023406224028
   PubMed Web of Science ®Google Scholar
• de Fátima Menegoci Eugênio P, Assunção NA, Sciandra F, Aquino A, Brancaccio A, Carrilho E. Quantification, 2DE analysis and identification of enriched glycosylated proteins from mouse muscles: difficulties and alternatives. Electrophoresis. 2016;37:321–334. doi:10.1002/elps.201500362
   PubMed Web of Science ®Google Scholar
• Machon O, Baldini SF, Ribeiro JP, et al. Recombinant fungal lectin as a new tool to investigate O-GlcNAcylation processes. Glycobiology. 2017;27(2):123–128. doi:10.1093/glycob/cww105
   PubMed Web of Science ®Google Scholar
• Audfray A, Beldjoudi M, Breiman A, et al. A recombinant fungal lectin for labeling truncated Glycans on human cancer cells. PLoS One. 2015;10(6):22. doi:10.1371/journal.pone.0128190
   Web of Science ®Google Scholar
• Liu W, Han G, Yin Y, et al. AANL (Agrocybe aegerita lectin 2) is a new facile tool to probe for O-GlcNAcylation. Glycobiology. 2018;28(6):363–373. doi:10.1093/glycob/cwy029
   PubMed Web of Science ®Google Scholar
• Su Y, Ye X, Xu B, et al. CBS homogenization mutation strategy narrows the glycan binding profile of a GlcNAc-specific lectin AANL. Glycobiology. 2020;30(3):159–173. doi:10.1093/glycob/cwz089
   PubMed Web of Science ®Google Scholar
• Mukwaya V, Zhang PP, Guo HZ, et al. Lectin-Glycan-mediated nanoparticle docking as a step toward programmable membrane catalysis and adhesion in synthetic protocells. ACS Nano. 2020;14(7):7899–7910. doi:10.1021/acsnano.0c02127
   PubMed Web of Science ®Google Scholar
• Duan XY, Cheng YF, Sang F, et al. Enhanced targeting function and anti-colon cancer efficacy by wheat germ agglutinin-modified nanoparticles for matrine delivery. Int J Pharmacol. 2020;16(6):470–478. doi:10.3923/ijp.2020.470.478
   Web of Science ®Google Scholar
• Martínez-Carmona M, Lozano D, Colilla M, Vallet-Regí M. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. Acta Biomater. 2018;65:393–404. doi:10.1016/j.actbio.2017.11.007
   PubMed Web of Science ®Google Scholar
• Corbo C, Molinaro R, Tabatabaei M, Farokhzad OC, Mahmoudi M. Personalized protein Corona on nanoparticles and its clinical implications. Biomater Sci. 2017;5(3):378–387. doi:10.1039/C6BM00921B
   PubMed Web of Science ®Google Scholar
• Pinals RL, Chio L, Ledesma F, Landry MP. Engineering at the nano-bio interface: harnessing the protein Corona towards nanoparticle design and function. Analyst. 2020;145(15):5090–5112. doi:10.1039/D0AN00633E
   PubMed Web of Science ®Google Scholar
• Chen D, Ganesh S, Wang W, Amiji M. Protein Corona-enabled systemic delivery and targeting of nanoparticles. AAPS J. 2020;22(4):83. doi:10.1208/s12248-020-00464-x
   PubMed Web of Science ®Google Scholar
• Fasoli E. Protein Corona: Dr. Jekyll and Mr. Hyde of nanomedicine. Biotechnol Appl Biochem. 2021;68(6):1139–1152. doi:10.1002/bab.2035
   PubMed Web of Science ®Google Scholar
• Farshbaf M, Valizadeh H, Panahi Y, et al. The impact of protein Corona on the biological behavior of targeting nanomedicines. Int J Pharm. 2022;614:121458. doi:10.1016/j.ijpharm.2022.121458
   PubMed Web of Science ®Google Scholar
• Francia V, Yang K, Deville S, Reker-Smit C, Nelissen I, Salvati A. Corona composition can affect the mechanisms cells use to internalize nanoparticles. ACS Nano. 2019;13(10):11107–11121. doi:10.1021/acsnano.9b03824
   PubMed Web of Science ®Google Scholar
• Hajipour MJ, Raheb J, Akhavan O, et al. Personalized disease-specific protein Corona influences the therapeutic impact of graphene oxide. Nanoscale. 2015;7(19):8978–8994. doi:10.1039/C5NR00520E
   PubMed Web of Science ®Google Scholar
• Chio L, Del Bonis-O’Donnell JT, Kline MA, et al. Electrostatic assemblies of single-walled carbon nanotubes and sequence-tunable peptoid polymers detect a lectin protein and its target sugars. Nano Lett. 2019;19(11):7563–7572. doi:10.1021/acs.nanolett.8b04955
   PubMed Web of Science ®Google Scholar
• Li X, Yang G, Guan F. Preparation and application of lectin modified magnetosomes. J Biol. 2015;32(6):96–99.
   Google Scholar
• Ferreira JA, Daniel-da-silva AL, Alves RMP, et al. Synthesis and optimization of tectin functionalized nanoprobes for the selective recovery of Glycoproteins from human body fluids. Anal Chem. 2011;83(18):7035–7043. doi:10.1021/ac200916j
   PubMed Web of Science ®Google Scholar
• Parker LM, Reineck P, Ghanii-Fard M, et al. Utilising glycobiology for fluorescent nanodiamond uptake and imaging in the central nervous system. Paper presented at: 2019 PhotonIcs & Electromagnetics Research Symposium - Spring (PIERS-Spring); June 17–20, 2019; 2019; Italy.
   Google Scholar
• Pooja D, Kulhari H, Kuncha M, et al. Improving efficacy, oral bioavailability, and delivery of paclitaxel using protein-grafted solid lipid nanoparticles. Mol Pharm. 2016;13(11):3903–3912. doi:10.1021/acs.molpharmaceut.6b00691
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Kandi R, Rao CP. Wheat germ agglutinin modified magnetic iron oxide nanocomplex as a cell membrane specific receptor target material for killing breast cancer cells. J Mat Chem B. 2018;6(36):5729–5737. doi:10.1039/C8TB01170B
   PubMed Web of Science ®Google Scholar
• Verathamjamras C, Sriwitool T-E, Netsirisawan P, et al. Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer. Glycoconj J. 2021;38(1):55–65. doi:10.1007/s10719-021-09978-8
   PubMed Web of Science ®Google Scholar
• Yan Y, Ding H. pH-responsive nanoparticles for cancer immunotherapy: a brief review. Nanomaterials. 2020;10(8):1613. doi:10.3390/nano10081613
   Web of Science ®Google Scholar
• Akhavan O, Ghaderi E. Graphene nanomesh promises extremely efficient in vivo photothermal therapy. Small. 2013;9(21):3593–3601. doi:10.1002/smll.201203106
   PubMed Web of Science ®Google Scholar
• Ouyang A, Zhao D, Wang X, Zhang W, Jiang T. Covalent RGD-graphene-phthalocyanine nanocomposite for fluorescence imaging-guided dual active/passive tumor-targeted combinatorial phototherapy. J Mater Chem B. 2022;10(2):306–320. doi:10.1039/D1TB02254G
   PubMed Web of Science ®Google Scholar
• Wang S, Yu G, Wang Z, et al. Hierarchical tumor microenvironment-responsive nanomedicine for programmed delivery of chemotherapeutics. Adv Mater. 2018;30:e1803926–e1803926. doi:10.1002/adma.201803926
   Web of Science ®Google Scholar
• Sun CY, Shen S, Xu CF, et al. Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc. 2015;137(48):15217–15224. doi:10.1021/jacs.5b09602
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kwon O-S. O-GlcNAc transferase inhibitor synergistically enhances doxorubicin-induced apoptosis in HepG2 cells. Cancers. 2020;12(11):3154. doi:10.3390/cancers12113154
   PubMed Web of Science ®Google Scholar
• Itkonen HM, Poulose N, Steele RE, et al. Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Mol Cancer Res. 2020;18(10):1512–1521. doi:10.1158/1541-7786.MCR-20-0339
   PubMed Web of Science ®Google Scholar
• Lin TL, Rizzieri DA, Ryan DH, et al. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021;5(6):1719–1728. doi:10.1182/bloodadvances.2020003510
   PubMed Web of Science ®Google Scholar